These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33992717)

  • 1. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
    Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H
    Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
    Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
    JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
    Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
    Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
    Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
    Grønberg BH; Halvorsen TO; Fløtten Ø; Brustugun OT; Brunsvig PF; Aasebø U; Bremnes RM; Tollåli T; Hornslien K; Aksnessæther BY; Liaaen ED; Sundstrøm S;
    Acta Oncol; 2016 May; 55(5):591-7. PubMed ID: 26494411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
    Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
    Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F
    Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
    Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
    BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Grønberg BH; Killingberg KT; Fløtten Ø; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
    Lancet Oncol; 2021 Mar; 22(3):321-331. PubMed ID: 33662285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
    Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE
    J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
    Le QT; Moon J; Redman M; Williamson SK; Lara PN; Goldberg Z; Gaspar LE; Crowley JJ; Moore DF; Gandara DR
    J Clin Oncol; 2009 Jun; 27(18):3014-9. PubMed ID: 19364954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
    Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study.
    Chen LK; Huang H; Liao H; Liu GZ; Zeng YD; Dinglin XX; Xu GC; Wei WD
    Med Oncol; 2012 Sep; 29(3):1687-92. PubMed ID: 21853344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.